This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Omenn syndrome오멘증후군

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D81.8 (other specified combined immunodeficiencies) | OMIM: 603554 | ORPHA: ORPHA:39041 | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsOmenn syndrome, Familial reticuloendotheliosis with eosinophilia, SCID Omenn type, Hypomorphic RAG deficiency (Omenn phenotype)
C. Adult onsetLikelihood of first presentation in adulthood: very low — an infantile disease that typically presents within a few weeks to 6 months after birth; survival to adulthood occurs only with treatment, and reaching adulthood without treatment is nearly impossible.
1. History1965 first description by Gilbert S. Omenn as "familial reticuloendotheliosis with eosinophilia" → 1996~1999 partial loss-of-function (hypomorphic) mutations in RAG1/RAG2 identified as the cause → Omenn phenotypes due to variants in genes other than RAG are now also recognized.
2. CausesPartial loss-of-function (hypomorphic) mutation in the RAG1 or RAG2 gene → incomplete V(D)J recombination → limited T-cell receptor diversity → peripheral infiltration of autoreactive T cells → excessive inflammatory response. Variants in other genes such as ARTEMIS and IL2RG can also cause the Omenn phenotype.
3. GeneticsAutosomal recessive (RAG1 11p13, RAG2 11p13) or X-linked (IL2RG). Many partial loss-of-function variants, such as RAG1 Arg624His and RAG2 Arg229Gln. Complete loss-of-function variants cause typical SCID.
4. General epidemiologyMore than 200 cases reported worldwide. Estimated incidence about 1/500,000~1/1,000,000 births. Equal in males and females (RAG) or mainly affecting boys (IL2RG X-linked). Very few reports in Korea.
5. PathophysiologyPartially functional RAG → restricted TCR/BCR repertoire → oligoclonal T-cell expansion → activation of autoreactive Th2 T cells → elevated IgE, eosinophilia, organ infiltration → mixed immunodeficiency + autoinflammatory phenotype.
6. SymptomsErythroderma, alopecia, hepatosplenomegaly, lymphadenopathy, failure to thrive, recurrent opportunistic infections, chronic diarrhea.
7. SignsT cells present (oligoclonal), B cells absent or very few, markedly elevated IgE, overall decrease in serum immunoglobulins, eosinophilia, lack of TCR repertoire diversity.
8. ScreeningTREC-based newborn screening (T-cell counts normal to reduced; variable TREC results), serum IgE·eosinophil screening, early genetic testing based on family history.
9. DiagnosisT-cell oligoclonality analysis (TCR spectratyping), serum IgE quantification, eosinophil count, confirmation of absent B cells (CD19), molecular genetic testing (RAG1/RAG2/ARTEMIS, etc.), skin histopathology.
10. TreatmentHSCT (curative). Immunosuppression before HSCT (steroids, cyclosporine) to suppress autoreactive T cells. Prophylactic anti-infectives, IVIG, skin care, live vaccines contraindicated.
11. PrognosisLong-term survival is possible with successful HSCT (60~80%). Immunosuppression before HSCT is important for improving transplant success. Without treatment, early death from recurrent infections and multi-organ inflammation.
12. PreventionGenetic counseling, PGT/prenatal genetic diagnosis, TREC newborn screening, infection prevention before HSCT, skin protection, live vaccines contraindicated.
13. ReferencesOmenn GS. Familial reticuloendotheliosis with eosinophilia … and 9 other papers

1. History

Omenn syndrome is a disease first described in 1965 by the American physician Gilbert Stanley Omenn in the New England Journal of Medicine. Omenn reported a distinctive clinical syndrome observed in two siblings under 6 months of age as "familial reticuloendotheliosis with eosinophilia." These children showed a characteristic syndrome of universal erythroderma, alopecia, hepatosplenomegaly, lymphadenopathy, eosinophilia, failure to thrive and recurrent infections. Omenn intuitively grasped that these findings arose not from a simple allergy or skin disease but from a serious abnormality of the immune system itself, but with the immunological knowledge of the time it was difficult to establish the exact mechanism.

For decades thereafter, Omenn syndrome was described mainly as a clinical syndrome, and cases with various immune phenotypes were reported from around the world. In the 1980s, it was observed that in patients with Omenn syndrome T cells are present but their diversity is restricted (oligoclonal T cell expansion), and that these T cells are autoreactive. This paradoxical phenotype, in which abundant T cells coexist with severe immunodeficiency, was also called "SCID with oligoclonal T cell expansion."

In 1996, a Dutch research group discovered partial loss-of-function (hypomorphic) mutations in the RAG1 (recombination activating gene 1) gene in patients with Omenn syndrome. In 1999, Corneo et al. also identified similar partial loss-of-function mutations in RAG2. These discoveries revealed that the core mechanism of Omenn syndrome lies not in complete loss of RAG function (which causes typical B−T−NK+ SCID) but in partial permissiveness of T-cell receptor (TCR) V(D)J recombination by incompletely functioning RAG proteins. It was established that restricted T cells generated with incompletely rearranged TCRs are released to the periphery without sufficient negative selection in the thymus, become autoreactive and attack the body's own tissues, causing excessive inflammatory reactions such as erythroderma.

Since the 2000s, it has become clear that, in addition to RAG1/RAG2, partial loss-of-function variants in several genes such as ARTEMIS, IL2RG (a gene associated with X-linked SCID), IL7R and ADA can cause a phenotype identical or similar to Omenn syndrome. Omenn syndrome has thus come to be understood not as a single disease caused by a specific gene defect, but as a clinical phenotype arising from partial loss of function of RAG and other genes involved in V(D)J recombination. It is registered as D81.8 (other specified combined immunodeficiencies) in ICD-10, 603554 in OMIM and ORPHA:39041 in Orphanet.


2. Causes

The most common cause of Omenn syndrome is a partial loss-of-function (hypomorphic) mutation in the RAG1 or RAG2 gene. RAG1 and RAG2 form an enzyme complex that catalyzes V(D)J recombination of antigen receptor genes (T-cell receptor and B-cell receptor immunoglobulin) during the development of lymphocytes (T cells and B cells).

In normal V(D)J recombination, the RAG1-RAG2 complex recognizes the recombination signal sequences (RSS) between variable (V), diversity (D) and joining (J) gene segments, cleaves the DNA, and creates enormous receptor diversity through random segment selection and joining. With complete loss-of-function RAG mutations, V(D)J recombination does not occur at all, resulting in typical B−T−NK+ SCID, in which no mature T or B cells are produced.

In contrast, with partial loss-of-function (hypomorphic) mutations, the enzymatic activity of the RAG protein is not completely lost but partly retained. In this case, V(D)J recombination is incomplete and biased, and only a very limited number of successful rearrangements are permitted. As a result, only a small number of T-cell clones with a very restricted TCR repertoire (oligoclonal TCR diversity) are generated. The T cells generated in this process do not sufficiently undergo normal negative selection and include autoreactive T cells that respond to self-antigens. Their infiltration of peripheral tissues, causing excessive inflammatory reactions (mainly Th2-skewed), is the core pathophysiology of Omenn syndrome.

Causes other than RAG1/RAG2 reported to produce an Omenn syndrome-like phenotype include partial loss-of-function variants in the ARTEMIS gene, which is involved in repairing DNA double-strand breaks during V(D)J recombination, partial loss-of-function variants in IL2RG (γ chain, common gamma chain) (X-linked), and partial loss-of-function variants in the IL7Rα chain. Omenn syndrome is therefore not a single-gene disease but a combined immunodeficiency-autoinflammatory phenotype that can arise from partial loss of function of multiple genes involved in T-cell development.


3. Genetics

RAG1/RAG2 deficiency, the most common cause of Omenn syndrome, follows autosomal recessive (AR) inheritance. The RAG1 gene (Gene ID: 5896) and RAG2 gene (Gene ID: 5897) are both located side by side at position 13 of the short arm of chromosome 11 (11p13), about 8 kb apart and transcribed in opposite directions.

RAG1 encodes a protein of 1,040 amino acids (about 119 kDa) and RAG2 a protein of 527 amino acids (about 59 kDa). The RAG1-RAG2 complex is responsible for RSS recognition, DNA cleavage and processing of cleaved ends in the V(D)J recombination reaction. The partial loss-of-function variants that cause the Omenn syndrome phenotype are located at positions that damage the enzyme's active site or major domains without causing complete inactivation. The most frequently reported variants include RAG1 p.Arg624His (c.1871G>A), RAG1 p.Arg394Trp, RAG2 p.Arg229Gln (c.686G>A) and RAG2 p.His519Pro. These variants are characterized by residual RAG protein functioning partially and permitting limited V(D)J recombination.

A genotype-phenotype correlation has been established in which complete loss-of-function variants cause typical B−T−NK+ SCID while partial loss-of-function (hypomorphic) variants in the same gene cause Omenn syndrome. In compound heterozygotes, the sum of residual RAG activity of the two alleles is important in determining the Omenn vs. typical SCID phenotype. Omenn syndrome due to IL2RG variants is X-linked (XL) and therefore manifests only in boys. Molecular genetic diagnosis is performed by NGS of a primary immunodeficiency panel including RAG1, RAG2, ARTEMIS, IL2RG and others, or by WES.


4. General epidemiology

Omenn syndrome is a rare disease worldwide. Since its first description in 1965, more than about 200 cases are estimated to have been reported in the scientific literature worldwide. The incidence is estimated at about 1 in 500,000~1,000,000 births, but as diagnostic rates improve with the expansion of newborn TREC screening and advances in NGS diagnostic technology, the actual frequency may be higher. The sex distribution is equal for RAG1/RAG2 variants (AR inheritance), whereas IL2RG variants (XL inheritance) manifest only in boys. Frequency may be increased in populations with high rates of consanguineous marriage.

Data from international primary immunodeficiency registries (ESID registry, PIDTC) report that about 5~10% of all SCID shows the Omenn syndrome phenotype. Considering that the incidence of SCID is estimated at 1 in 50,000~100,000 births, Omenn syndrome, as one of the special phenotypes of SCID, is relatively not uncommon. In Korea, confirmed cases of Omenn syndrome are very rare, and some are presumed to be registered under code D81.8 in health insurance claims data. Detection rates in Korea are expected to improve as newborn screening and molecular diagnostic infrastructure expand.


5. Pathophysiology

The pathogenesis of Omenn syndrome is understood as a distinctive pathway: incomplete V(D)J recombination by partially functioning RAG proteins → restricted TCR diversity → peripheral expansion of autoreactive T cells → coexistence of immunodeficiency and excessive autoinflammation.

Incomplete V(D)J recombination and restricted TCR diversity

In the normal thymus, T-cell precursors generate hundreds of millions or more diverse T-cell clones, each with different antigen specificity, through V(D)J recombination of TCR genes by the RAG1-RAG2 complex. With partially functional RAG, V(D)J recombination occurs in an extremely limited and biased manner. As a result, the peripheral T-cell pool shows a monoclonal or oligoclonal pattern in which very few clones have proliferated excessively. These T cells with a restricted TCR repertoire include autoreactive T cells that have not sufficiently undergone normal negative selection.

Peripheral infiltration of autoreactive T cells and excessive inflammation

Autoreactive T cells released into the periphery are activated mainly with a Th2-skewed phenotype. They oversecrete Th2 cytokines such as IL-4, IL-5 and IL-13, activating mast cells and eosinophils. This results in a marked rise in blood IgE and blood and tissue eosinophilia. Activated T cells infiltrate peripheral tissues such as the skin, intestine, liver and spleen, causing inflammation. T-cell infiltration of the skin causes erythroderma, a specific finding characterized by reddening, scaling and shedding of the skin over the whole body. At the same time, B cells are barely produced because of partial loss of RAG function, so B-cell numbers are markedly reduced and serum immunoglobulins (IgG, IgA, IgM) are generally low, impairing antibody-based immunity.

Paradoxical coexistence of immunodeficiency and autoinflammation

The clinical paradox of Omenn syndrome is that, on the one hand, there is severe immunodeficiency due to T-cell oligoclonality (absence of B cells, loss of functional TCR diversity, susceptibility to opportunistic infections), and on the other hand, there is an excessive inflammatory response due to activated autoreactive T cells (erythroderma, hepatosplenomegaly, lymphadenopathy, elevated blood IgE and eosinophils), both at the same time. This paradoxical coexistence is the key pathophysiological feature distinguishing Omenn syndrome from other types of SCID, and it presents unique challenges in both diagnosis and treatment.


6. Symptoms

Omenn syndrome is characterized by a distinctive clinical picture in which symptoms of immunodeficiency and autoinflammation coexist.

Skin symptoms

Erythroderma is the most characteristic finding in Omenn syndrome. The skin of the whole body becomes extensively red and sheds like scales, and the surface becomes dry and thickened. Alopecia due to destruction of hair follicles commonly accompanies it. The skin is sometimes severely itchy, and secondary skin infections occur easily. On skin findings alone, it must be differentiated from severe atopic dermatitis, Stevens-Johnson syndrome, neonatal lupus and others.

Symptoms of immunodeficiency-related infection

Recurrent opportunistic infections occur, particularly Pneumocystis jirovecii pneumonia (PJP), candidiasis (oral, skin, esophageal), disseminated CMV infection and Salmonella sepsis. The first severe infection often occurs within a few weeks to months after birth. When live vaccines (BCG, etc.) are given, disseminated BCG infection (BCGosis) can occur and be fatal.

Systemic symptoms

Hepatosplenomegaly is prominent, reflecting infiltration of the liver and spleen by activated T cells and histiocytes. Lymphadenopathy may also appear generalized, in contrast to other types of SCID in which lymph nodes are small or absent. Chronic or recurrent diarrhea, failure to thrive (FTT) due to malabsorption and protein-losing enteropathy may occur. Jaundice and liver dysfunction are also observed in some patients.


7. Signs

The laboratory findings of Omenn syndrome show a distinctive pattern that distinguishes it from other types of SCID.

Hematologic findings

On the peripheral blood complete blood count, eosinophilia is characteristic. Eosinophil counts are generally increased to 2~3 times or more the upper limit of normal and in severe cases may account for more than 20~40% of the WBC. Lymphocyte counts vary and may be normal or increased in some patients (unlike other types of SCID).

Lymphocyte subset findings

On flow cytometry, T cells (CD3+) are present, but their numbers are often irregular and the CD4/CD8 ratio abnormal. B cells (CD19+) are markedly reduced or absent. NK cells (CD16+/CD56+) are normal or increased. TCR repertoire analysis (TCR spectratyping) shows an oligoclonal or monoclonal expansion pattern. T-cell function tests (PHA proliferative response) vary and may be normal or mildly reduced.

Immunoglobulins and IgE

A marked rise in serum IgE is one of the most characteristic laboratory findings of Omenn syndrome. It rises to very high levels for age (often 1,000~10,000 IU/mL or more). In contrast, IgG, IgA and IgM are low or absent, impairing antibody defense. Specific IgE may be positive to multiple allergens on RAST or CAP testing, but this reflects nonspecific IgE elevation due to the Th2 skewing of T cells rather than true allergic reactions.

Pathologic findings

Skin biopsy shows T-lymphocyte infiltration of the epithelial layer, epidermal thickening (acanthosis) and dyskeratosis. Lymph node biopsy (if performed) shows loss of normal lymphocyte architecture and oligoclonal T-cell infiltration.


8. Screening

Newborn screening for Omenn syndrome is more complex in some respects than for other types of T-cell deficiency, because on TREC screening T-cell numbers may appear normal or even increased, with a risk of missing the diagnosis.

Role and limitations of TREC-based newborn screening

Because T-cell numbers may be normal or increased in Omenn syndrome, TREC counts may also appear at normal levels. However, these T cells do not have normal TCR diversity, so the diversity of TRECs is limited. In some TREC tests the TREC count itself is low, because the T cells are often not newly produced by the thymus but have proliferated oligoclonally in the periphery. Therefore, when a TREC abnormality (reduction) is found, Omenn syndrome should also be included in the differential diagnosis. However, even if TRECs are normal, Omenn syndrome should be actively suspected when erythroderma, eosinophilia, hepatosplenomegaly and failure to thrive are present clinically.

IgE and eosinophil screening

At the initial immune evaluation, measurement of serum IgE and checking the blood eosinophil count are important clues suggesting Omenn syndrome. When unexplained elevation of serum IgE and eosinophilia occur together in an infant, Omenn syndrome is suspected, and TCR diversity analysis and molecular genetic testing follow.

Family history-based screening and early genetic testing

When a sibling is affected or the parents are confirmed carriers, lymphocyte subset analysis, TCR diversity analysis (TCR spectratyping) and targeted RAG1/RAG2 variant analysis are performed immediately after birth.


9. Diagnosis

Confirmation of Omenn syndrome requires integrating characteristic clinical findings, immunological tests, TCR diversity analysis and molecular genetic testing.

Immunophenotyping

Flow cytometry measures the numbers and proportions of T cells (CD3+, CD4+, CD8+), B cells (CD19+) and NK cells. The typical pattern in Omenn syndrome is T cells present (normal or increased), B cells markedly reduced or absent, and NK cells normal. It is important to note, however, that the presence of T cells does not mean normal immune function.

TCR repertoire analysis (TCR spectratyping)

The distribution of TCR Vβ segment usage in peripheral blood T cells is analyzed to confirm oligoclonal or monoclonal expansion. Normally, various Vβ segments are used in a Gaussian distribution, but in Omenn syndrome an oligoclonal pattern in which particular Vβ segments are predominantly selected is observed. TCR spectratyping or next-generation sequencing-based immune repertoire sequencing is used.

Serum IgE and immunoglobulins

Serum IgE markedly elevated above the age-expected value (often thousands of IU/mL) together with reduced or absent IgG, IgA and IgM strongly suggests Omenn syndrome.

Molecular genetic confirmation

The causative variant is confirmed by NGS of a primary immunodeficiency panel including RAG1, RAG2, ARTEMIS, IL2RG and others. Ideally, the functional characteristics of the identified variant (complete vs. partial loss of function) are verified by a RAG function assay (measurement of in vitro V(D)J recombination activity).

Skin and lymph node histopathology

On skin biopsy, T-lymphocyte infiltration, epidermal thickening and dyskeratosis support the diagnosis. Histopathological findings may resemble adult CTCL (cutaneous T-cell lymphoma) and require differentiation.


10. Treatment

The curative treatment for Omenn syndrome is HSCT, and immunosuppressive treatment before HSCT to suppress excessive tissue damage by autoreactive T cells is important for improving transplant success rates.

Immunosuppressive treatment before HSCT

In Omenn syndrome, immunosuppressive treatment to suppress autoreactive T cells is recommended before HSCT. Typically, combination therapy with cyclosporine + steroids (prednisolone) is used. This relieves excessive inflammatory reactions such as erythroderma, hepatosplenomegaly and lymphadenopathy and achieves clinical stabilization so that HSCT can proceed. During immunosuppressive treatment, prevention of opportunistic infections becomes even more important.

Hematopoietic stem cell transplantation (HSCT)

HSCT is the only curative therapy for Omenn syndrome. After conditioning, normal hematopoietic stem cells are transplanted to reconstitute T cells and B cells with normal RAG function. Transplantation from an HLA-matched sibling donor is ideal, and transplantation from unrelated and haploidentical donors is also attempted. For conditioning, myeloablative conditioning (MAC) is generally preferred in order to completely eliminate autoreactive T cells and defective immune cells. After transplantation, immunosuppressive therapy to prevent graft-versus-host disease (GVHD) is given alongside.

Supportive care

Before and after HSCT, TMP-SMX (PJP prophylaxis), antifungals, antivirals (preemptive CMV treatment), IVIG (regular administration), skin care (moisturizers, topical steroids, infection prevention), absolute contraindication of live vaccines, and use of irradiated blood products for transfusion are needed.


11. Prognosis

The prognosis of Omenn syndrome is determined by whether and when HSCT is performed and by the effect of pre-transplant immunosuppressive treatment. Without treatment, most patients die in infancy from recurrent opportunistic infections and multi-organ inflammatory damage. When HSCT is successfully performed, long-term survival is reported at about 60~80%, somewhat lower than for other types of SCID. This is because organ damage due to chronic inflammation before HSCT (hepatosplenomegaly, intestinal damage, etc.) and a poor transplant environment work against transplant success. Transplant success rates improve when transplantation is performed after autoreactive T cells have been suppressed and the clinical condition stabilized with pre-HSCT immunosuppression. After HSCT, once T cells and B cells are reconstituted, TCR diversity recovers and immune function normalizes. Long-term survivors need long-term follow-up for transplant-related complications such as GVHD, PTLD and endocrine dysfunction.


12. Prevention

Prevention of Omenn syndrome consists of reducing genetic risk, early diagnosis, and preventing infectious and inflammatory complications.

Primary prevention: genetic counseling and reproductive choices

Carrier parents of an affected child are informed of the 25% risk of an affected child in the next pregnancy. Affected embryos/fetuses are identified by PGT or prenatal genetic diagnosis (CVS/amniocentesis). In families with X-linked IL2RG variants, prenatal diagnosis linked to determination of fetal sex is possible.

Secondary prevention: newborn screening and early diagnosis

When TREC reduction is found on TREC-based newborn screening, or when erythroderma, eosinophilia, failure to thrive and the like appear clinically, immediate immune function evaluation (TCR diversity, IgE, lymphocyte subsets) and molecular genetic testing follow. After early diagnosis, immunosuppressive treatment and infection prevention are provided before HSCT preparation.

Tertiary prevention: management of complications after HSCT

After HSCT, immune reconstitution, GVHD, PTLD, endocrine function, neurodevelopment and growth are assessed regularly. Infection prophylaxis is maintained until full recovery of immune function, and whether live vaccination can be resumed is decided in consultation with an immunologist.


13. References

  1. Omenn GS. Familial reticuloendotheliosis with eosinophilia. New England Journal of Medicine. 1965;273(8):427–432. DOI: 10.1056/NEJM196508192730806. PMID: 14337093.

  2. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998;93(5):885–896. DOI: 10.1016/S0092-8674(00)81448-8. PMID: 9630231.

  3. Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97(9):2772–2776. DOI: 10.1182/blood.v97.9.2772. PMID: 11313271.

  4. Pasic S, Cupic M, Jovanovic T, et al. Omenn syndrome with reduced expression of HLA class II on lymphocytes in a patient with RAG2 mutation. Immunology Letters. 2009;123(1):79–83. DOI: 10.1016/j.imlet.2009.02.009. PMID: 19268690.

  5. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe and beyond the year 2000. Journal of Allergy and Clinical Immunology. 2010;126(3):602–610. DOI: 10.1016/j.jaci.2010.06.015. PMID: 20709388.

  6. Lambrecht BN, Hammad H. The immunology of asthma and Omenn syndrome. Journal of Allergy and Clinical Immunology. 2012;129(6):1482–1490. DOI: 10.1016/j.jaci.2012.04.038. PMID: 22607749.

  7. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.

  8. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nature Reviews Immunology. 2016;16(4):234–246. DOI: 10.1038/nri.2016.28. PMID: 27001178.

  9. Dvorak CC, Haddad E, Buckley RH, et al. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era. Blood Advances. 2019;3(19):2918–2926. DOI: 10.1182/bloodadvances.2019000882. PMID: 31575493.

  10. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. New England Journal of Medicine. 2014;371(5):434–446. DOI: 10.1056/NEJMoa1401177. PMID: 25075835.